Vivos Therapeutics (VVOS) Price to Sales (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Price to Sales for 7 consecutive years, with 1.27 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 79.06% year-over-year to 1.27 in Q2 2026; TTM through Jun 2026 was 0.31, a 80.54% decrease from a year earlier, with the FY2025 full-year figure at 1.08, down 35.7% from the prior year.
• Price to Sales was 1.27 for Q2 2026 at Vivos Therapeutics, down from 3.1 in the prior quarter.
• Over five years, Price to Sales peaked at 16.92 in Q1 2022 and troughed at 1.27 in Q2 2026.
• A 5-year average of 4.92 and a median of 4.48 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales slumped 87.07% in 2023 and surged 225.3% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 2.34 in 2022, then surged by 99.42% to 4.67 in 2023, then surged by 46.29% to 6.83 in 2024, then decreased by 27.85% to 4.93 in 2025, then sank by 74.26% to 1.27 in 2026.
• The last three Price to Sales figures came in at 1.27 (Q2 2026), 3.1 (Q1 2026), and 4.93 (Q4 2025), per Business Quant data.